See more : Anna Infrastructures Limited (ANNAINFRA.BO) Income Statement Analysis – Financial Results
Complete financial analysis of OTR Acquisition Corp. (OTRA) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of OTR Acquisition Corp., a leading company in the Shell Companies industry within the Financial Services sector.
You may be interested
- Henderson Opportunities Trust plc (HOT.L) Income Statement Analysis – Financial Results
- Israel Corporation Ltd (IRLCF) Income Statement Analysis – Financial Results
- Arfin India Limited (ARFIN.BO) Income Statement Analysis – Financial Results
- ALPHA Corporation (3434.T) Income Statement Analysis – Financial Results
- Soochow Securities Co., Ltd. (601555.SS) Income Statement Analysis – Financial Results
OTR Acquisition Corp. (OTRA)
About OTR Acquisition Corp.
As of May 19, 2022, OTR Acquisition Corp. was acquired by Comera Life Sciences Holdings, Inc., in a reverse merger transaction. OTR Acquisition Corp. does not have significant operations. It focuses on effecting a merger, share exchange, asset acquisition, stock purchase, recapitalization, reorganization, or other business combination with one or more businesses or entities. The company was incorporated in 2020 and is based in Miami, Florida.
| Metric | 2021 | 2020 |
|---|---|---|
| Revenue | 0.00 | 0.00 |
| Cost of Revenue | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% |
| Research & Development | 0.00 | 0.00 |
| General & Administrative | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 |
| SG&A | 0.00 | 0.00 |
| Other Expenses | 1.05M | -208.69K |
| Operating Expenses | 1.05M | -208.69K |
| Cost & Expenses | 1.05M | -208.69K |
| Interest Income | 37.68K | 0.00 |
| Interest Expense | -5.74M | 0.00 |
| Depreciation & Amortization | 5.74M | 9.16K |
| EBITDA | 4.69M | -199.53K |
| EBITDA Ratio | 0.00% | 0.00% |
| Operating Income | -1.05M | -208.69K |
| Operating Income Ratio | 0.00% | 0.00% |
| Total Other Income/Expenses | 5.74M | 9.16K |
| Income Before Tax | 4.69M | -199.53K |
| Income Before Tax Ratio | 0.00% | 0.00% |
| Income Tax Expense | -5.74M | 0.00 |
| Net Income | 10.43M | -199.53K |
| Net Income Ratio | 0.00% | 0.00% |
| EPS | 0.79 | -0.02 |
| EPS Diluted | 0.79 | -0.02 |
| Weighted Avg Shares Out | 13.24M | 13.24M |
| Weighted Avg Shares Out (Dil) | 13.24M | 13.24M |
Comera Life Sciences Debuts as Publicly Traded Company Focused on Transforming Biologics
WOBURN, Mass.--(BUSINESS WIRE)--Comera Life Sciences Holdings, Inc. (“Comera” or the “Company”), which is developing a new generation of bio-innovative biologic medicines to improve patient access, safety, and convenience, today announced the completion of its business combination with OTR Acquisition Corp....
Why Is OTR Acquisition (OTRA) Stock Up Today?
The shares of OTR Acquisition are climbing after the SPAC's shareholders overwhelmingly approved a merger with Comera. The post Why Is OTR Acquisition (OTRA) Stock Up Today?
Comera Life Sciences Announces Research Collaboration with Top 10 Pharmaceutical Company to Develop Subcutaneous Formulation
WOBURN, Mass.--(BUSINESS WIRE)--Comera Life Sciences, Inc. (“Comera” or the “Company”), which is developing a new generation of bio-innovative biologic medicines to improve patient access, safety, and convenience, today announced it has entered into a research collaboration with a top 10...
Comera Life Sciences to Present at 18th Annual PEGS Boston Conference & Expo
WOBURN, Mass.--(BUSINESS WIRE)--Comera Life Sciences, Inc., which is developing a new generation of bio-innovative biologic medicines to improve patient access, safety, and convenience, today announced that Robert P. Mahoney, Ph.D., Chief Scientific Officer, will present at the PEGS Boston Conference...
Comera Life Sciences and Intas Pharmaceuticals Announce Research Collaboration
WOBURN, Mass. & AHMEDABAD, India--(BUSINESS WIRE)--Today, Comera Life Sciences, Inc. (“Comera” or the “Company”) and Intas Pharmaceuticals Ltd. (“Intas”) announced a research collaboration to develop a new generation of bio-innovative biologic medicines to improve patient access, safety, and convenience. Under...
Comera Life Sciences and OTR Acquisition Corp. Announce Effectiveness of Registration Statement for Proposed Business Combination
WOBURN, Mass. & MIAMI--(BUSINESS WIRE)--Comera Life Sciences, Inc. (“Comera”), which is developing a new generation of bio-innovative biologic medicines to improve patient access, safety, and convenience, and OTR Acquisition Corp. (Nasdaq: OTRA) (“OTR”), a publicly traded special purpose acquisition company...
OTR Acquisition Corp. Announces Confidential Submission of S-4 Registration Statement Related to Proposed Business Combination
MIAMI--(BUSINESS WIRE)--OTR Acquisition Corp. (Nasdaq: OTRAU, OTRA and OTRAW), a publicly traded special purpose acquisition company (SPAC), today announced the confidential submission with the U.S. Securities and Exchange Commission (“SEC”) of a draft registration statement on Form S-4 (the “Registration...
OTR Acquisition Corp. Announces Confidential Submission of S-4 Registration Statement Related to Proposed Business Combination
MIAMI--(BUSINESS WIRE)--OTR Acquisition Corp. (Nasdaq: OTRAU, OTRA and OTRAW), a publicly traded special purpose acquisition company (SPAC), today announced the confidential submission with the U.S. Securities and Exchange Commission (“SEC”) of a draft registration statement on Form S-4 (the “Registration...
Comera Life Sciences to Become Publicly Traded via Business Combination with OTR Acquisition Corp.
WOBURN, Mass. & MIAMI--(BUSINESS WIRE)--Comera Life Sciences, Inc. (“Comera” or the “Company”), which is developing a new generation of bio-innovative biologic medicines to improve patient access, safety, and convenience, and OTR Acquisition Corp. (Nasdaq: OTRAU, OTRA and OTRAW) (collectively referred...
Source: https://incomestatements.info
Category: Stock Reports